An Open-label Phase I Study of Once Every Three Weeks Intravenous Treatment With BI 6727 in Japanese Patients With Advanced Solid Tumours.

Trial Profile

An Open-label Phase I Study of Once Every Three Weeks Intravenous Treatment With BI 6727 in Japanese Patients With Advanced Solid Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2015

At a glance

  • Drugs Volasertib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 02 Dec 2015 Results published in the Investigational New Drugs
    • 25 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 May 2014 Planned End Date changed from 1 Aug 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top